Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tagliaferri

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
European Journal of Neurology|February 24, 2017
Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trialF Pagnini, A Marconi, A Tagliaferri, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 25, 2010
Spectrum of F8 gene mutations in haemophilia A patients from a region of Italy: identification of 23 new mutationsF Riccardi, A Tagliaferri, D Martorana, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2012
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand diseaseG Castaman, A Coppola, E Zanon, et al.
Cancer Discovery|April 17, 2019
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, et al.
Journal for Immunotherapy of Cancer|April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M Tannir, Daniel C Cho, Adi Diab, et al.
European Urology|June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.
Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.
Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 15, 2011
Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitorsE Zanon, A Iorio, A Rocino, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
European Journal of Neurology|February 24, 2017
Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trialF Pagnini, A Marconi, A Tagliaferri, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 25, 2010
Spectrum of F8 gene mutations in haemophilia A patients from a region of Italy: identification of 23 new mutationsF Riccardi, A Tagliaferri, D Martorana, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2012
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand diseaseG Castaman, A Coppola, E Zanon, et al.
Cancer Discovery|April 17, 2019
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, et al.
Journal for Immunotherapy of Cancer|April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M Tannir, Daniel C Cho, Adi Diab, et al.
European Urology|June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.
Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.
Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 15, 2011
Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitorsE Zanon, A Iorio, A Rocino, et al.
Pageof 9